CPIX - Cumberland Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.065
-0.055 (-0.772%)
As of 1:39PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.120
Open7.130
Bid7.060 x 500
Ask7.070 x 200
Day's Range7.065 - 7.120
52 Week Range5.280 - 7.960
Volume4,984
Avg. Volume11,327
Market Cap111.26M
Beta0.54
PE Ratio (TTM)N/A
EPS (TTM)-0.499
Earnings DateMar 5, 2018 - Mar 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • American City Business Journals22 days ago

    The fastest-growing Nashville health care company of 2017 might surprise you

    Nashville is well known for the collection of health care providers that call Music City home. Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company founded in 1999, has seen its stock price rise more than 33 percent to $7.35, and as high as 44 percent, since the beginning of the year. Community Healthcare Trust Inc.’s stock price has risen second-fastest at almost 22 percent, as of today.

  • Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Excessively Paying Its CEO?
    Simply Wall St.23 days ago

    Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Excessively Paying Its CEO?

    A. Kazimi took the helm as Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) CEO and grew market cap to $116.38M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Who Owns Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)?
    Simply Wall St.last month

    Who Owns Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)?

    In this article, I’m going to take a look at Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Cumberland Pharmaceuticals Inc (CPIX): How Much Growth Is Left In Healthcare?
    Simply Wall St.2 months ago

    Cumberland Pharmaceuticals Inc (CPIX): How Much Growth Is Left In Healthcare?

    Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), a USD$125.35M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • Capital Cube2 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : November 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CPIX earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
    Capital Cube2 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, Pernix Therapeutics Holdings, Inc., DURECT Corporation, Akorn, Inc., Merck & Co., Inc., Mylan N.V., Sucampo Pharmaceuticals, Inc. Class A ... Read more (Read more...)

  • Associated Press2 months ago

    Cumberland reports 3Q loss

    On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 5 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 1 cent per share. The pharmaceutical ...

  • PR Newswire2 months ago

    Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter

    - Launched Totect® in the United States - Implemented Kristalose® Co-Promotion Agreement NASHVILLE, Tenn. , Nov. 7, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical ...

  • ACCESSWIRE2 months ago

    Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 ...

  • PR Newswire3 months ago

    Cumberland Pharmaceuticals to Announce Third Quarter 2017 Financial Results

    NASHVILLE, Tenn. , Oct. 31, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2017 financial results after the market closes on Tuesday, ...

  • Should You Be Holding Cumberland Pharmaceuticals Inc (CPIX) Right Now?
    Simply Wall St.3 months ago

    Should You Be Holding Cumberland Pharmaceuticals Inc (CPIX) Right Now?

    If you are a shareholder in Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Capital Cube3 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube3 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 8.67 million, Net Earnings of USD -5.16 million. Gross margins narrowed from 76.47% to 73.21% compared to the same period last year, operating (EBITDA) margins now -11.86% from 6.53%. Change in operating ... Read more (Read more...)

  • PR Newswire4 months ago

    Cumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention

    NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.

  • What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?
    Simply Wall St.4 months ago

    What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?

    If you are a shareholder in Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Associated Press5 months ago

    Cumberland reports 2Q loss

    On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 32 cents. Losses, adjusted for pretax expenses and non-recurring costs, were 5 cents per share. The pharmaceutical company ...

  • PR Newswire5 months ago

    Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter

    - Revenues Grew 17% Over the Prior Year Period - New Co-Promotion Agreement for Kristalose® added NASHVILLE, Tenn. , Aug. 8, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty ...

  • ACCESSWIRE5 months ago

    Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at ...

  • PR Newswire6 months ago

    Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results

    NASHVILLE, Tenn. , Aug. 1, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2017 financial results after the market closes on Tuesday, ...

  • PR Newswire6 months ago

    Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support

    NASHVILLE, Tenn., July 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing dexrazoxane, sold under the brand name Totect®, to U.S. wholesalers today. Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.

  • Capital Cube6 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : July 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Cumberland Pharmaceuticals, Inc. : May 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube8 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, Pernix Therapeutics Holdings, Inc., DURECT Corporation, Mylan N.V., Merck & Co., Inc., Akorn, Inc., Pfizer Inc. and Sucampo Pharmaceuticals, ... Read more (Read more...)